Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Rigel Pharmaceuticals, Inc. (RIGL) had Stock-Based Compensation of $3.32M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$53.33M |
|
$11.45M |
|
$4.41M |
|
$48.92M |
|
$40.56M |
|
$12.77M |
|
$-1.26M |
|
$11.51M |
|
$11.51M |
|
$11.45M |
|
$11.45M |
|
$11.45M |
|
$11.45M |
|
$12.77M |
|
$13.19M |
|
17.81M |
|
18.17M |
|
$0.64 |
|
$0.63 |
|
| Balance Sheet Financials | |
$146.56M |
|
$0.08M |
|
$29.41M |
|
$175.97M |
|
$66.63M |
|
$44.93M |
|
$90.78M |
|
$157.41M |
|
$18.57M |
|
$-7.95M |
|
$18.57M |
|
17.87M |
|
| Cash Flow Statement Financials | |
$-0.89M |
|
$-10.55M |
|
$0.48M |
|
$56.75M |
|
$45.78M |
|
$-10.96M |
|
|
Stock-Based Compensation |
$3.32M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.20 |
|
-- |
|
-- |
|
0.71 |
|
3.22 |
|
91.73% |
|
23.95% |
|
23.95% |
|
-- |
|
21.58% |
|
21.46% |
|
$-0.89M |
|
-- |
|
-- |
|
-- |
|
0.30 |
|
0.95 |
|
1.28 |
|
70.11 |
|
61.65% |
|
-144.07% |
|
6.50% |
|
18.03% |
|
$1.04 |
|
$-0.05 |
|
$-0.05 |
|